Characterizing T cell responses in chikungunya virus infection
Active Grant Awarded
- Award ID
- F31AI197833
- Recipient
-
University Of California, San Diego UEI UYTTZT6G9DT1
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $43,489
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 11% complete
- Place of performance
- La Jolla, CA 92093, USA
Award details come from USAspending.gov.
Description
- Abstract
- Chikungunya virus (CHIKV) is a RE-emerging neglected tropical alphavirus transmitted by mosquitoes and is known for its capability to induce debilitating chronic arthralgia and inflammation in patients for months to years post-infection. Despite recurrent outbreaks and ongoing vaccine development efforts, our understanding of immune responses to CHIKV in human populations experiencing chronic disease is largely limited. Additionally, even less work has been done to study immune responses to other arthritogenic alphaviruses, which is a sub-group of alphaviruses that are known to also cause arthritis-like symptoms post-infection, similar to CHIKV. To address a critical GAP in our understanding of the development of chronic disease, the overall goal of this study is to comprehensively characterize immune responses, particularly T-cell responses, to CHIKV and other alphaviruses in individuals with long-term arthritis-like symptoms post-infection. My previous work has shown that T cells play an essential role in CHIKV pathogenesis. Using EX vivo peptide-based T cell stimulation and high-resolution spectral flow cytometry, I found that CHIKV-specific CD4+ T cells are more frequent in the peripheral blood of patients with chronic symptoms as opposed to those who have recovered. Previous studies in mice and non-human primates have also suggested a pathogenic role of CD4+ T cells in disease pathogenesis. Building on this intriguing observation, I hypothesize that CD4+ T cells play a pathogenic role in CHIKV infection in humans and could be responsible for the development of chronic arthritis-like symptoms and inflammation. To test this hypothesis, I propose two specific aims for the study. First, I intend to better characterize the transcriptional profile and functional phenotype of CHIKV-specific memory effector CD4+ T cells in individuals with chronic disease by performing high dimensional single-cell RNA sequencing of antigen-specific effector and regulatory CD4+ T cells. Second, I aim to determine whether CHIKV-specific T cells are cross-reactive with other arthritogenic and encephalitic alphaviruses that CO-circulate with CHIKV by first mapping cross-reactive regions in other alphaviruses and assessing T cell phenotype in an in vitro and EX vivo T cell assay. Overall, my project will provide a comprehensive landscape of the T cell immune profile in CHIKV and other alphavirus infections and deepen our understanding of how T cell responses are modulated in chronic diseases.
Quick answers
Who received award F31AI197833?
F31AI197833 was awarded to University Of California, San Diego by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 24, 2026.
How much is award F31AI197833 worth?
$43,489 has been obligated on F31AI197833.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award